Scholarlink

Objectives <p>To estimate the proportion of children aged 9–12&#xa0;years with seroprotective antibody titers against mumps following a single dose of measles–mumps–rubella (MMR) vaccine administered in early childhood, and to explore the association between seroprotection and clinicodemographic profile.</p> Methods <p>A cross-sectional study was conducted at a tertiary hospital in Delhi between April 2024 and August 2025. Children aged 9–12&#xa0;years with a documented receipt of a single dose of MMR vaccine at 16–24&#xa0;months of age were recruited. Two mL of venous blood was collected and analyzed for serum mumps-specific IgG antibodies using enzyme-linked immunosorbent assay (ELISA), with seroprotection defined as mumps antibody titers ≥ 22 RU/mL. The association between seroprotection and demographic and clinical variables, including age, sex, age at vaccination, and nutritional status, was assessed using the chi-square test or Fisher’s exact test.</p> Results <p>Eighty-six children (48% males) aged 9–12&#xa0;years [mean (SD) 10.35 (1.04) years] were enrolled. Overall, 84.8% demonstrated seroprotective antibody titers against mumps. The median (q1, q3) mumps-specific IgG titer was 97.6 (46.1, 144.9) RU/mL. Children aged &gt; 10&#xa0;years were significantly more likely to be seronegative compared to younger children (OR 3.99, 95% CI 1.07, 14.92, <i>P</i> = 0.039).</p> Conclusion <p>Nearly 85% of children who had received a single MMR dose at 16–24&#xa0;months of age had seroprotective mumps antibody titers at 9–12&#xa0;years. The findings highlight the need for larger community-based studies on the durability of mumps immunity and add to the accumulating evidence informing future MMR vaccination strategies in India.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Seroprotection Against Mumps in MMR Vaccinated Children Aged 9–12 Years: A Cross-Sectional Study

  • 期刊论文

  • 发表日期：

    2026年7月30日

查看全文
  • Dhairya Bansal,
  • Aaradhana,
  • Bineeta Kashyap,
  • Anju Aggarwal,
  • Debamita Banik

摘要

Objectives

To estimate the proportion of children aged 9–12 years with seroprotective antibody titers against mumps following a single dose of measles–mumps–rubella (MMR) vaccine administered in early childhood, and to explore the association between seroprotection and clinicodemographic profile.

Methods

A cross-sectional study was conducted at a tertiary hospital in Delhi between April 2024 and August 2025. Children aged 9–12 years with a documented receipt of a single dose of MMR vaccine at 16–24 months of age were recruited. Two mL of venous blood was collected and analyzed for serum mumps-specific IgG antibodies using enzyme-linked immunosorbent assay (ELISA), with seroprotection defined as mumps antibody titers ≥ 22 RU/mL. The association between seroprotection and demographic and clinical variables, including age, sex, age at vaccination, and nutritional status, was assessed using the chi-square test or Fisher’s exact test.

Results

Eighty-six children (48% males) aged 9–12 years [mean (SD) 10.35 (1.04) years] were enrolled. Overall, 84.8% demonstrated seroprotective antibody titers against mumps. The median (q1, q3) mumps-specific IgG titer was 97.6 (46.1, 144.9) RU/mL. Children aged > 10 years were significantly more likely to be seronegative compared to younger children (OR 3.99, 95% CI 1.07, 14.92, P = 0.039).

Conclusion

Nearly 85% of children who had received a single MMR dose at 16–24 months of age had seroprotective mumps antibody titers at 9–12 years. The findings highlight the need for larger community-based studies on the durability of mumps immunity and add to the accumulating evidence informing future MMR vaccination strategies in India.